Blue Owl Capital has been upgraded to a strong buy due to its resilient fundraising, having raised over $44 billion in the past year and maintaining $30 billion in dry powder. The company reported robust Q1 earnings with fee-related earnings of $0.25 per share and a 15% year-over-year growth in assets under management. Its forward dividend yield is attractive at 9.3%, supported by a $0.92 per share payout commitment. Valuation is compelling at 11 times forward P/E compared to the industry average of 19.5 times, with future growth expected from AI infrastructure and real assets fundraising.
Emerson Electric announced a collaboration with Saudi Aramco to co-develop next-generation corrosion management solutions using ultrasonic online monitoring and wireless technology. This partnership aims to improve operational safety and performance ...
Natural Grocers, a leading organic grocery retailer, is opening its first store in Wisconsin on June 10, 2026, in Lake Geneva. The grand opening will feature giveaways, discounts, a prize wheel, and a $2,500 donation to the Lake Geneva Food Pantry, h...
Current inflation trends in the U.S. are often compared to the 1970s stagflation, but experts highlight key differences. Unlike the 1970s, today's inflation is driven mainly by supply-side pressures such as rising commodity prices and geopolitical te...
Dycom Industries reported a record first quarter with contract revenues up 56.1% to $1.965 billion and adjusted net income nearly doubling to $134.3 million. The company raised its full-year fiscal 2027 revenue outlook to $7.38-$7.65 billion, driven ...
Autolus Therapeutics, a biopharmaceutical company specializing in next-generation T cell therapies, announced it will present at two upcoming investor conferences: William Blair’s Growth Stock Conference on June 2 and Jefferies Global Healthcare Conf...
